dihydronicotinamide riboside

Dihydronicotinamide riboside is a reduced nicotinamide riboside analogue and an NAD^+^ precursor. It is a small molecule that, when administered to mammalian cells or mice, substantially increases NAD^+^ concentrations more potently than other precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NRH is rapidly taken up and acts as a biochemical precursor for NAD^+^ biosynthesis, via a pathway that does not involve the regular NR kinases (Nrk1/Nrk2), but includes ATP-dependent kinase activity converting NRH to dihydronicotinamide mononucleotide (NMNH). It is also utilized preferentially by the quinone oxidoreductase enzyme NQO2 as a reductant. The mechanism of action involves direct enhancement of cellular NAD^+^ and modulation of redox state but does not inhibit NAD^+^ consumption. Its increased potency has led to interest in its use as a supplement and research tool in metabolic and aging studies. In certain cell types, excessive NRH can induce cytotoxicity via increased ROS and mitochondrial perturbation, indicating cell-type sensitivity and the need for further safety research[1][5][7].

Other names

1,4-dihydronicotinamide ribosideNRH